SMS Pharmaceuticals Results Update
SMS Pharmaceuticals released a press release on its Q2 and H1 FY27 results, showing strong growth. Management now expects FY27 revenue growth and EBITDA margins above earlier guidance.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
SMS Pharmaceuticals released a press release on its Q2 and H1 FY27 results, showing strong growth. Management now expects FY27 revenue growth and EBITDA margins above earlier guidance.
SMS Pharmaceuticals reported Q1FY27 revenue of ₹207 crore, up 6% YoY. The board also approved a ₹50 crore loan infusion into its subsidiary, SMS Peptides.
SMS Pharmaceuticals reported FY26 revenue of ₹886.87 Crore, a 13% YoY increase. Net profit surged 47% to ₹101.98 Crore, driven by backward integration and mix.